Device Trial Radar · NCT01907828
A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence
Last checked: Nov 19, 2026Latest source record: May 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Apr 15, 2014
Primary completion
Oct 15, 2018
Study completion Oct 15, 2018
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jul 25, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post market clinical investigation is to complete preliminary evaluation on whether or not concomitant renal denervation with the EnligHTN™ Renal Denervation System and cardiac ablation will result in improved outcomes as compared to ablation alone in patients with uncontrolled hypertension being treated for Atrial Fibrillation
Conditions
- Persistent Atrial Fibrillation
- Paroxysmal Atrial Fibrillation
- Hypertension
Interventions
Renal Artery AblationDevice
Renal artery denervation using the EnligHTN™ Renal Denervation System
Cardiac AblationDevice
Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Freedom From Atrial Fibrillation at 12 MonthTime frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Herzzentrum Dresden GmbH Universitätsklinik
Dresden, Germany
Herzzentrum Leipzig GmbH
Leipzig, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.